Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Melanoma and other skin tumours

1079MO - Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)

Date

18 Sep 2020

Session

Mini Oral - Melanoma and other skin tumours

Topics

Targeted Therapy

Tumour Site

Melanoma

Presenters

Peter Lau

Citation

Annals of Oncology (2020) 31 (suppl_4): S672-S710. 10.1016/annonc/annonc280

Authors

P.K.H. Lau1, B. Feran2, L. Smith3, A. Lasocki4, R. Molania2, K. Smith1, A. Weppler1, C. Angel5, D. Kee1, P. Bhave6, B. Lee1, H.X. Aw Yeang7, I. Vergara8, D. Kok9, K. Drummond10, P. Neeson7, K. Sheppard3, T. Papenfuss2, S. Sandhu1, G. McArthur1

Author affiliations

  • 1 Medical Oncology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 2 Bioinformatics, Walter and Eliza Institute of Medical Research, 3052 - Parkville/AU
  • 3 Oncogenic Signalling Laboratory, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 4 Radiology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 5 Histopathology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 6 Medical Oncology, The Alfred Hospital, Melbourne/AU
  • 7 Cancer Research, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 8 Bioinformatics, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 9 Radiation Oncology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 10 Neurosurgery, Royal Melbourne Hospital, 3000 - Melbourne/AU
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1079MO

Background

Melanoma CNS metastases are a common problem that causes high morbidity and mortality. Although first line dabrafenib-trametinib and ipilimumab-nivolumab (I-N) have similar intracranial response rates (50-55%), durable responses are only seen with combination immunotherapy and CNS resistance to BRAF-MEK inhibitors (BRAF-MEKi) usually occurs within 6 months. We sought to investigate the utility of I-N after BRAF-MEKi CNS progression and identify resistance mechanisms.

Methods

All patients receiving second/third line I-N for CNS metastases from 1/3/15 to 1/8/18 with prior progression on BRAF-MEKi and MRI brain staging were included. Modified intracranial RECIST was used to assess response. Formalin fixed paraffin embedded samples of BRAF V600 mutant CNS metastases naïve to treatment (n=18) or excised after progression on BRAF-MEKi (n=14) underwent whole transcriptome sequencing. Comparative analyses of CNS samples naïve to systemic treatment versus BRAF-MEKi progression was performed.

Results

Thirty patients received second/third line I-N with median CNS diameter of 21 mm. Modest efficacy of I-N after BRAF-MEKi progression was observed with an intracranial response rate of 4.8% (1/21) and median PFS of 5.5 weeks. Given the poor activity of I-N after BRAF-MEKi CNS progression we investigated the mechanisms that also conferred resistance to immunotherapy. We identified 179 differentially expressed genes (DEG) between naïve and BRAF-MEKi progression CNS metastases (p < 0.05, false discovery rate [FDR] < 0.1). Gene set enrichment analysis with KEGG, GO or Hallmark libraries did not identify distinct pathways. Enrichment of DEG from the Innate anti-PD1 Resistance Signature (IPRES) was identified (p < 0.01, FDR = 0.03). Macrophage associated chemokines and myeloid activation genes were upregulated in CNS progression samples. Histological assessment showed increased macrophage grading in BRAF-MEKi progression samples (mean 1.45 vs 0.45, p=0.009).

Conclusions

I-N after CNS BRAF-MEKi progression has modest intracranial activity. CNS metastases resistant to BRAF-MEKi showed expression of the IPRES gene signature and upregulation of myeloid cell activation markers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

P.K.H. Lau: Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Pfizer. D. Kee: Honoraria (self), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy: Novartis. P. Neeson: Research grant/Funding (self): Bristol-Myers Squibb. S. Sandhu: Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Amgen; Honoraria (self): Merk Sharp & Dohme; Honoraria (self): Janssen. G. McArthur: Research grant/Funding (institution), Principal Investigator of clinical trials with the following commercial entities (all revenues payed to my institution as reimbursement for trial- costs): Bristol-Myers Squibb; Research grant/Funding (institution), Principal Investigator of clinical trials with the following commercial entities (all revenues payed to my institution as reimbursement for trial- costs): Array BioPharm; Research grant/Funding (institution), Principal Investigator of clinical trials with the following commercial entities (all revenues payed to my institution as reimbursement for trial- costs): Amgen; Research grant/Funding (institution), Principal Investigator of clinical trials with the following commercial entities (all revenues payed to my institution as reimbursement for trial- costs): Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.